Followers | 145 |
Posts | 27561 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, September 30, 2016 7:14:33 AM
TEL AVIV, Israel, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (“EI” or the “Company”) (EMITF) (EMITF) announced today, in further to its announcement dated on December 2, 2015, regarding an agreement to sell 100% of its interest in a special purpose vehicle which holds a site in Bangalore, India by Elbit Plaza India Real Estate Holdings Limited (“EPI” - a joint venture company of EI and its 45% subsidiary, Plaza Centers N.V.) to a local investor , the following matters:
The Sale of the project in Bangalore has not been completed until the long stop date, September 30, 2016 (the "LSD").
As a result, the Company and the Local Investor has reached these preliminary understandings:
a. The Local Investor will pay EPI an advance payment of 5 Crore Rupees (approximately €0.65 million) prior to 30.9.2016.
b. The securities provided by the Local Investor to EPI under the Sale Agreement will remain effective and unchanged (the "Securities").
c. Subject to the payment of the First Advance Payment, the LSD will be extended until November 15, 2016.
d. The Local Investor will pay additional advance payments (the "Additional Advance Payments") as follows:
i. 32 Crore rupees (approximately €4.3 million) in two instalments during the fourth quarter of 2016.
ii. Additional 22.5 Crore rupees (approximately €3 million) during the second quarter of 2017.
e. Subject to the execution of all the Additional Advance Payments, the LSD will be extended until September 15, 2017.
f. If the Local Investor will fail to execute any of the advance payments, than EPI shall be able to enforce its rights under the Sale Agreement including the execution of the Securities.
At this preliminary stage, there is no definitive agreement between EPI and the Local Investor and there is no certainty that any of the aforementioned understandings will be executed.
In case the parties will not reach such final agreement, EPI will consider its further steps with respect to the Sale Agreement, including, inter alia, the execution of the Securities.
The Company will update regarding any new developments.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM